<DOC>
	<DOCNO>NCT01146951</DOCNO>
	<brief_summary>To confirm combination therapy rufinamide superior efficacy compare placebo patient Lennox-Gastaut syndrome .</brief_summary>
	<brief_title>A Placebo-Controlled , Double-Blind Comparative Study E2080 Lennox-Gastaut Syndrome Patients ( Study E2080-J081-304 )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lennox Gastaut Syndrome</mesh_term>
	<criteria>Inclusion criterion 1 . Participants diagnose LennoxGastaut syndrome tonic/atonic seizure atypical absence seizure ( A history atypical absence seizure also incorporate ) . 2 . Participants slow spikeandwave pattern electroencephalogram within 6 month prior enrollment Observation Period . 3 . Participants least total 90 seizure 28 day prior enrollment Observation Period . 4 . Participants 1 3 antiepileptic drug 28 day prior enrollment Observation Period change type antiepileptic drug . 5 . Participants change type dose administration antiepileptic drug take Observation Period . Exclusion criterion ; 1 . Participants history generalize tonicclonic status epilepticus within baseline . 2 . Participants receive drug therapy least 4 time rescue status epilepticus within baseline . 3 . Participants history hypoxia need emergency resuscitation within 12 month prior Treatment Period . 4 . Participants ketogenic diet receive adrenocorticotropic hormone ( ACTH ) therapy Vitamin B6 therapy within 6 month prior Treatment Period . 5 . Participants history suicide attempt within 1 year prior Treatment Period . 6 . Participants history allergy triazole compound . 7 . Participants clinically significant electrocardiogram abnormality baseline . 8 . Participants pregnant , may pregnant , lactate wish pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Seizures</keyword>
</DOC>